📊 BCAB Key Takeaways
Is BioAtla, Inc. (BCAB) a Good Investment?
BioAtla faces an imminent financial crisis with negative stockholders' equity of -$37.3M, indicating technical insolvency. The company has only $2.0M cash against a $5.3M annual burn rate, providing approximately 4-5 months of runway, and a critical liquidity crisis (0.15x current ratio) with zero revenue and significant operating losses.
BioAtla's fundamentals are very weak: it remains pre-revenue, deeply loss-making, and is operating with negative equity and sub-1.0 liquidity ratios. While net loss and diluted EPS improved year over year, the balance sheet and cash burn profile suggest financing dependence remains the dominant fundamental driver until the company demonstrates durable revenue generation or a materially longer cash runway.
BioAtla, Inc. Key Strengths (BCAB)
- Net losses narrowing YoY (+14.6% improvement) and EPS improving (+29.9% YoY) suggest operational efficiency gains
- Early-stage biotech business model is expected to operate at losses during pre-commercialization phases
- Insider activity observed (7 Form 4 filings in last 90 days) indicates management engagement
- Net loss improved 43.5% year over year, indicating some reduction in earnings pressure
- Diluted EPS improved 44.2% year over year, showing lower per-share loss versus the prior period
- No long-term debt is disclosed, so financial stress appears driven more by operating losses than debt servicing
BCAB Stock Risks: BioAtla, Inc. Investment Risks
- Negative stockholders' equity of -$37.3M means liabilities exceed assets; company is technically insolvent
- Severe liquidity crisis with current ratio of 0.15x and only ~4 months of cash remaining at current burn rate
- Zero revenue with $9.3M annual operating losses and no clear near-term path to profitability
- Will require emergency capital raise or debt restructuring within months to avoid bankruptcy
- ROA of -74.1% indicates extreme asset inefficiency and value destruction
- The business generated no revenue in the latest period, so growth quality is currently unproven
- Negative stockholders' equity and a 0.54x current ratio indicate a highly strained financial position
- Operating cash outflow of $40.29M against only $8.32M of cash implies significant near-term funding risk
Key Metrics to Watch
- Cash runway and timing of next capital raise (survival metric)
- Operating burn rate trends and path to revenue generation
- Pipeline progress toward FDA approval or commercial partnerships
- Debt restructuring activities or dilutive equity offerings
- Form 4 insider activity patterns (indicator of management confidence/exit activity)
- Quarterly operating cash burn relative to cash and equivalents
- Any sustained revenue generation from collaborations, milestones, or product-related commercialization
BioAtla, Inc. (BCAB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BCAB Profit Margin, ROE & Profitability Analysis
BCAB vs Healthcare Sector: How BioAtla, Inc. Compares
How BioAtla, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioAtla, Inc. Stock Overvalued? BCAB Valuation Analysis 2026
Based on fundamental analysis, BioAtla, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioAtla, Inc. Balance Sheet: BCAB Debt, Cash & Liquidity
BCAB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioAtla, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.44 indicates the company is currently unprofitable.
BCAB Revenue Growth, EPS Growth & YoY Performance
BCAB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$25.8M | $-0.69 |
| Q2 2023 | N/A | -$28.9M | $-0.75 |
| Q1 2023 | N/A | -$24.3M | $-0.58 |
| Q3 2022 | N/A | -$22.9M | $-0.68 |
| Q2 2022 | N/A | -$28.9M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioAtla, Inc. Dividends, Buybacks & Capital Allocation
BCAB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioAtla, Inc. (CIK: 0001826892)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCAB
What is the AI rating for BCAB?
BioAtla, Inc. (BCAB) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCAB's key strengths?
Claude: Net losses narrowing YoY (+14.6% improvement) and EPS improving (+29.9% YoY) suggest operational efficiency gains. Early-stage biotech business model is expected to operate at losses during pre-commercialization phases. ChatGPT: Net loss improved 43.5% year over year, indicating some reduction in earnings pressure. Diluted EPS improved 44.2% year over year, showing lower per-share loss versus the prior period.
What are the risks of investing in BCAB?
Claude: Negative stockholders' equity of -$37.3M means liabilities exceed assets; company is technically insolvent. Severe liquidity crisis with current ratio of 0.15x and only ~4 months of cash remaining at current burn rate. ChatGPT: The business generated no revenue in the latest period, so growth quality is currently unproven. Negative stockholders' equity and a 0.54x current ratio indicate a highly strained financial position.
What is BCAB's revenue and growth?
BioAtla, Inc. reported revenue of $0.0.
Does BCAB pay dividends?
BioAtla, Inc. does not currently pay dividends.
Where can I find BCAB SEC filings?
Official SEC filings for BioAtla, Inc. (CIK: 0001826892) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCAB's EPS?
BioAtla, Inc. has a diluted EPS of $-4.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BCAB's fundamental grade?
Based on our AI fundamental analysis in June 2026, BioAtla, Inc. has a D grade with 93% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BCAB stock overvalued or undervalued?
Valuation metrics for BCAB: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BCAB's AI grade for 2026?
Our dual AI analysis gives BioAtla, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BCAB's free cash flow?
BioAtla, Inc.'s operating cash flow is $-5.3M, with capital expenditures of N/A.
How does BCAB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.15 (avg: 2).